Meglumine antimoniate

Meglumine antimoniate is a medicine used to treat leishmaniasis.^[1] This includes visceral, mucocutaneous, and cutaneous leishmaniasis.^[1] It is given by injection into a muscle or into the area infected.^[1]

Meglumine antimoniate

Clinical data
Other names	Meglumine antimonate
AHFS/Drugs.com	Micromedex Detailed Consumer Information
ATC code	P01CB01 (WHO) QP51DX01 (WHO)
Identifiers
IUPAC name Hydroxy-dioxostiborane; (2R,3R,4R,5S)-6-methylaminohexane-1,2,3,4,5-pentol
CAS Number	133-51-7 N
PubChem CID	64953
ChemSpider	58479 Y
UNII	75G4TW236W
ChEMBL	ChEMBL239129 Y
NIAID ChemDB	008733
CompTox Dashboard (EPA)	DTXSID4043935
ECHA InfoCard	100.004.645
Chemical and physical data
Formula	Variable
Molar mass	Variable
3D model (JSmol)	Interactive image
SMILES O=[Sb](=O)O.O[C@@H]([C@@H](O)[C@H](O)[C@@H](O)CNC)CO
InChI InChI=1S/C7H17NO5.H2O.2O.Sb/c1-8-2-4(10)6(12)7(13)5(11)3-9;;;;/h4-13H,2-3H2,1H3;1H2;;;/q;;;;+1/p-1/t4-,5+,6+,7+;;;;/m0..../s1 Y Key:XOGYVDXPYVPAAQ-SESJOKTNSA-M Y
NY (what is this?)  (verify)

Side effects include loss of appetite, nausea, abdominal pain, cough, feeling tired, muscle pain, irregular heartbeat, and kidney problems.^[1] It should not be used in people with significant heart, liver, or kidney problems.^[1] It is not recommended during breastfeeding.^[1] It belongs to a group of medications known as the pentavalent antimonials.^[1]

Meglumine antimoniate came into medical use in 1946.^[2] It is on the World Health Organization's List of Essential Medicines.^[3] It is available in Southern Europe and Latin America but not the United States.^[4][5]

Society and culture

It is manufactured by Aventis^[6] and sold as Glucantime in France, and Glucantim in Italy.

See also

• Meglumine